Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.32 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250114 | 0.77 | HTT (0.52) | MAPK1HTTKMT2A | |
| SCHEMBL16679057 | 0.77 | HTT (0.42) | HTTKMT2A | |
| SCHEMBL16679253 | 0.75 | MAPK1 (0.40) | MAPK1HTTKMT2ADDB1CRBN | |
| SCHEMBL16679762 | 0.75 | MAPK1 (0.44) | MAPK1 | |
| SCHEMBL16680514 | 0.73 | SRD5A1 (0.50) | MAPK1HTTKMT2A | |
| SCHEMBL28076438 | 0.73 | HTT (0.36) | HTTKMT2A | |
| SCHEMBL20746237 | 0.72 | CRBN (0.51) | MAPK1KMT2ADDB1CRBNIKZF3 | |
| SCHEMBL16678945 | 0.71 | MAPK1 (0.42) | MAPK1HTTKMT2A | |
| Formic Acid Methyl Ester SCHEMBL28076437 | 0.70 | HTR2A (0.40) | HTTKMT2APDE4B | |
| SCHEMBL16684521 | 0.70 | HTT (0.44) | MAPK1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| EP-3063143-B1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| EP-3063143-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885HTT 4048/4885KMT2A 431/4885 |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885HTT 4048/4885KMT2A 431/4885 |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885HTT 4048/4885KMT2A 431/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885HTT 4048/4885KMT2A 431/4885 |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885HTT 4048/4885KMT2A 431/4885 |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885HTT 4048/4885KMT2A 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.